Significance of nanomedicines and recent advancement in vaccine formulations for combating SARS-CoV2
by Dheeraj Bisht; Deepak Sati; Mohd Rashid; Rajeshwar Kamal Kant Arya
International Journal of Nanomanufacturing (IJNM), Vol. 18, No. 2, 2023

Abstract: Several lines of treatment for COVID-19 are being used worldwide, but to date, the perfect line of therapy is not available. Nanomedicines received success rates in past in treating various viral complications like HCV, HSV1, IAV, HuNoV, IBV, EBOV and HIV1, which could be a game-changer for COVID-19. Various manufacturing units are looking towards nanotechnology and evaluating different nanomedicines and vaccines for treating corona infection. Recently Pfizer achieved great success in developing liposome-based messenger ribonucleic acid vaccine called BNT162b. There are few nanoparticles (NPs) under clinical trials capable of neutralising SARS-CoV-2 in outer surrounding, e.g., GDs-NPs (Gold nanoparticles), Ag-NPs (Silver nanoparticles), CuO-NPs (Copper oxide nanoparticles). The mutation of virus is challenging for treating COVID-19 and intense discovery in field of nanoscience and clinical manifestation of COVID-19 is required. Authors described the significant role of lipid nanoparticles (LNPs) in different vaccine formulations and their utility in nanomedicines for management of COVID-19.

Online publication date: Tue, 04-Jul-2023

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Nanomanufacturing (IJNM):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com